Physician profile
Hauw Swan Lie
NPI 1083814248
$5,597.66
in general payments reported to CMS, 2019-2025
25 companies · $790 in 2025
The $790 reported for 2025 was more than what 84% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $769 · 2021: $1,132 · 2022: $566 · 2023: $557 · 2024: $793 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,140.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,242.25 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $728.69 | 2021-2025 | Dupixent |
| Genzyme Corporation | $727.36 | 2019-2025 | |
| Sobi, INC | $502.37 | 2019-2023 | |
| Covis Pharma Gmbh | $449.44 | 2019-2021 | |
| Baxter Healthcare | $390.77 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System |
| Glaxosmithkline, LLC. | $343.85 | 2019-2021 | |
| Philips North America LLC | $306.56 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Advanced Respiratory, INC | $218.44 | 2019-2021 | |
| Amgen INC. | $191.29 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $83.23 | 2020-2024 | Xolair |
| Teva Pharmaceuticals USA, INC. | $78.19 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $72.27 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.13 | 2020-2023 | Ofev |
| Azurity Pharmaceuticals, INC. | $35.53 | 2025 | Alvesco |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $27.29 | 2025 | Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $25.33 | 2024 | Elaprase |
| Alcresta Therapeutics, INC. | $22.94 | 2024 | Relizorb |
| Pharming Healthcare, INC. | $19.26 | 2024 | Ruconest |
| Electromed, INC. | $18.60 | 2025 | Smartvest |
| Sanofi Pasteur INC. | $17.38 | 2023 | |
| Merck Sharp & Dohme LLC | $17.31 | 2019 | |
| Aytu Biopharma, INC. | $15.77 | 2020 | |
| Circassia INC. | $13.52 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hauw Lie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.